
Sun Pharma Advanced Research Company Share Price Falls 4.40 Percent on 14 July 2026: Key Reasons
SPARC share price Rs 248.00, down 4.40% (Rs 11.42). Volume 15.65 lakh shares. Weak small cap pharma sentiment and broader market risk-off weigh on the R&D focused stock.
Updated: 14 Jul 2026 • 3:10 pm
Posted by:

The Sun Pharma Advanced Research Company share price fell 4.40 percent on 14 July 2026, with the stock quoting around Rs 248.00, down Rs 11.42 from the previous close of Rs 259.42. Trading volumes in the counter stood at 15,65,514 shares as the decline unfolded through the session, making SPARC one of the sharper decliners among small cap pharmaceutical and research linked stocks today.
Click Here – Get Free Investment Predictions
About Sun Pharma Advanced Research Company
Sun Pharma Advanced Research Company, commonly known as SPARC, was demerged from Sun Pharmaceutical Industries as a dedicated research and development entity focused on novel drug delivery systems and new chemical entities. Unlike its larger parent, SPARC does not have a large commercial manufacturing or sales base, and its financial performance is heavily tied to licensing income, milestone payments and the progress of its pipeline of experimental therapies, making the stock inherently more volatile and speculative than typical pharmaceutical companies.
Key Reasons Behind the SPARC Share Price Fall Today
The Sun Pharma Advanced Research Company share price decline today comes against a backdrop of broader market weakness, with the Nifty 50 and Sensex both trading lower amid escalating US-Iran tensions that have pushed crude oil prices higher and weighed on global risk appetite. India VIX, the market’s volatility gauge, was up around 1.7 to 1.8 percent today, reflecting elevated near term caution among traders across the board.
Beyond the broad market context, R&D focused pharmaceutical stocks like SPARC tend to see outsized price swings relative to more established pharma companies, since their valuations are driven less by predictable earnings and more by sentiment around pipeline progress, regulatory milestones and periodic newsflow. This dynamic is a key factor behind sharp single day moves in the Sun Pharma Advanced Research Company share price. In the absence of any large commercial revenue base to anchor valuations, such stocks are also more prone to profit booking after periods of speculative buying interest, which can produce sharp single day declines like today’s move.
SPARC Stock Performance Today
| Metric | Value |
|---|---|
| SPARC CMP | Rs 248.00 |
| Day Change | -4.40% |
| Change (Absolute) | -Rs 11.42 |
| Previous Close | Rs 259.42 |
| Volume | 15,65,514 shares |
Check SEBI Registered Investment Advisor Research on Univest
What This Means for SPARC Investors
The Sun Pharma Advanced Research Company share price today reflects this broader pattern of sentiment driven trading rather than a fundamental reassessment of the company’s pipeline value.
Given the speculative nature of the Sun Pharma Advanced Research Company share price, investors should be cautious about reading too much into a single session’s decline without a specific company disclosure explaining the move. Those tracking the stock should watch for any exchange filings on pipeline updates, licensing deals or regulatory developments that could better explain today’s sharper than market decline, and should size positions in a stock of this volatility profile accordingly.
Historically, moves in the Sun Pharma Advanced Research Company share price have shown limited correlation with the day to day performance of parent company Sun Pharmaceutical Industries, since SPARC’s valuation drivers are largely independent, tied instead to its own pipeline economics and periodic corporate developments. This makes the stock a distinct, higher risk proposition compared to broader pharmaceutical sector exposure, and investors should factor this differentiated risk profile into their overall portfolio construction.
Conclusion
The Sun Pharma Advanced Research Company share price fell 4.40 percent on 14 July 2026 amid broader market weakness and the stock’s inherently higher volatility as a research focused pharmaceutical entity. Investors should track any specific company disclosures and broader market direction before making fresh investment decisions.
Download the Univest iOS App or Univest Android App to track Sun Pharma Advanced Research Company share price live and get pharma sector updates.
Frequently Asked Questions
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Why did the Sun Pharma Advanced Research Company share price fall today?
Ans. The Sun Pharma Advanced Research Company share price fell 4.40 percent amid broader market weakness driven by US-Iran tensions and rising crude oil prices, compounded by the stock’s inherently higher volatility as a research focused pharmaceutical entity without a large commercial revenue base.
What was the SPARC share price today?
Ans. SPARC was quoting around Rs 248.00, down 4.40 percent or Rs 11.42, from its previous close of Rs 259.42 on 14 July 2026.
What does Sun Pharma Advanced Research Company do?
Ans. SPARC is a research and development focused entity demerged from Sun Pharmaceutical Industries, working on novel drug delivery systems and new chemical entities, with financial performance tied to licensing income and pipeline progress rather than large scale commercial sales.
Why are R&D focused pharma stocks like SPARC more volatile?
Ans. R&D focused pharma stocks tend to be more volatile because their valuations depend on sentiment around pipeline progress and regulatory milestones rather than predictable commercial earnings, making them prone to sharper price swings than established pharmaceutical companies.
What was the trading volume in SPARC shares today?
Ans. Trading volume in SPARC shares stood at 15,65,514 shares as of the time of this report on 14 July 2026.
Should I buy SPARC shares after today’s fall?
Ans. Investors should consult a SEBI-registered advisor and review any specific company disclosures before making an investment decision, given the stock’s speculative and volatile nature.
Recent Articles

Dhampur Bio Organics Q1 Results FY27: Company Turns Around with Rs 36.79 Crore Profit, Aided by Meerganj Unit Sale
14 July 2026

Jindal SAW Q1 Results FY27: PAT Plunges 75% to Rs 104.2 Crore as Margins Contract Sharply
14 July 2026

SG Finserve Q1 Results FY27: Net Profit Jumps 119% to Rs 53.7 Crore, Plans Rs 20 Crore Tech Acquisition
14 July 2026

Madhya Bharat Agro Q1 Results FY27: PAT Rises 17% to Rs 33 Crore Despite Stock Falling 5.3%
14 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Dhampur Bio Organics Q1 Results FY27: Company Turns Around with Rs 36.79 Crore Profit, Aided by Meerganj Unit Sale
Jindal SAW Q1 Results FY27: PAT Plunges 75% to Rs 104.2 Crore as Margins Contract Sharply
SG Finserve Q1 Results FY27: Net Profit Jumps 119% to Rs 53.7 Crore, Plans Rs 20 Crore Tech Acquisition
Madhya Bharat Agro Q1 Results FY27: PAT Rises 17% to Rs 33 Crore Despite Stock Falling 5.3%
Thermax Share Price Falls 5.25 Percent on 14 July 2026, Leading BSE Midcap Losers
Popular this week
Dhampur Bio Organics Q1 Results FY27: Company Turns Around with Rs 36.79 Crore Profit, Aided by Meerganj Unit Sale
Jindal SAW Q1 Results FY27: PAT Plunges 75% to Rs 104.2 Crore as Margins Contract Sharply
SG Finserve Q1 Results FY27: Net Profit Jumps 119% to Rs 53.7 Crore, Plans Rs 20 Crore Tech Acquisition
Madhya Bharat Agro Q1 Results FY27: PAT Rises 17% to Rs 33 Crore Despite Stock Falling 5.3%
Thermax Share Price Falls 5.25 Percent on 14 July 2026, Leading BSE Midcap Losers

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





